{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-019884","form_type":"8-K","ticker":"RZLT","cik":"0001509261","company_name":"Rezolute, Inc.","filed_at":"2024-02-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.420976+00:00","generated_at":"2026-06-06T03:21:59.410133+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Rezolute reports Q2 FY2024 net loss $13.9M; initiates Phase 3 for RZ358 in cHI","bullets":["Net loss of $13.9M for Q2 FY2024, compared to $13.6M same period prior year.","Cash, cash equivalents and investments $96.0M as of Dec 31, 2023, down from $118.4M at June 30, 2023.","Initiated sunRIZE Phase 3 study of RZ358 in congenital hyperinsulinism; topline results expected mid-2025.","Completed enrollment in Phase 2 study of RZ402 for diabetic macular edema; topline data expected Q2 2024.","Appointed Daron Evans as CFO, expanding leadership for late-stage development."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-019884","json":"https://secwatch.observer/filing/0001104659-24-019884.json","markdown":"https://secwatch.observer/filing/0001104659-24-019884.md","text":"https://secwatch.observer/filing/0001104659-24-019884.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924019884/0001104659-24-019884-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924019884/tm245849d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T03:21:59.410133+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"297f1c8d9bdc534e3a3f4ccd8af1ffc9e04b2106","claim":"Rezolute, Inc. reported second quarter of fiscal 2024 ended December 31, 2023 results: net income $13.9 million.","evidence_excerpt":"Net loss was $13.9 million for the second quarter of fiscal 2024, compared to $13.6 million for the same period in fiscal 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1509261/000110465924019884/0001104659-24-019884-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of fiscal 2024 ended December 31, 2023"},{"label":"Net income","value":"$13.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}